Recent performance snapshot

Veeva Systems (VEEV) has been on many investors’ radar after a challenging run, with the stock down about 27% year to date and about 31% over the past year.

Over the past month the share price fell about 2%, extending a past 3 months decline of roughly 11%, even as the company reports annual revenue of US$3.20b and net income of US$908.91m.

The stock’s short-term share price momentum has faded, with the 90 day share price return down 11.17% and the 1 year total shareholder return down 31.26%. This suggests investors are reassessing growth prospects and risks despite reported profitability.

If recent moves in Veeva Systems have you rethinking your exposure to healthcare technology, this could be a good moment to look at 34 healthcare AI stocks

With Veeva Systems posting annual revenue of about US$3.20b and net income near US$908.91m, yet trading well below some analyst targets, you need to ask: is this an undervalued growth story, or is the market already pricing in future gains?

Most Popular Narrative: 39.4% Undervalued

Compared with the last close at about $160.17, the most followed narrative pegs Veeva Systems’ fair value closer to $264, implying a sizeable gap that hinges on how its growth and profitability story plays out under an 8.0% discount rate.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud. This development is described as one that should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years. Veeva's rapid progress embedding advanced AI agents directly within its Vault platform, across both R&D and Commercial suites, is characterized as positioning the company as an essential workflow and automation partner amid the rising complexity of personalized medicine, genomics, and data-driven trials. This positioning is cited as potentially supporting higher pricing power, platform stickiness, and net margin expansion in the medium to long term.

Curious what has to happen for that higher fair value to make sense? The narrative leans on compound revenue gains, firmer margins, and a richer earnings multiple that assumes investors will keep paying up for this growth profile.

Result: Fair Value of $264.46 (UNDERVALUED)

However, this optimistic setup could unravel if CRM competition intensifies or if customers slow their adoption of Veeva’s AI driven products, which would put growth assumptions at risk.

Next Steps

With sentiment mixed across the article, it helps to look past the headlines and examine the underlying drivers yourself to decide where you stand. To see what the market is optimistic about right now, take a closer look at the 3 key rewards

Looking for more investment ideas?

If Veeva Systems has sharpened your focus, do not stop here. Some of the most interesting opportunities sit just outside the headlines, and you do not want to miss them.

• Spot potential bargains early by scanning screener containing 21 high quality undiscovered gems that combine strong underlying fundamentals with limited market attention.
• Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (46 results) for companies with robust finances that can better handle business setbacks.
• Focus on stability and sleep easier at night by checking 66 resilient stocks with low risk scores that score well on downside risk measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.